drugset

drugset / Trial / NCT01712178

A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Adalimumab for Pharmacokinetic, Pharmacodynamic and Safety

NCT01712178 ↗

Phase 2 Completed 100 enrolled AbbVie

RandomizedParallel-groupDouble-blindTreatment

Summary

A study in Rheumatoid Arthritis (RA) patients to evaluate two formulations of adalimumab for pharmacodynamics, pharmacokinetics, and safety.

Timeline

Start: 2012-06
Primary completion: 2013-05
Completion: 2013-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Adalimumab	Monoclonal antibody	40 mg	—

Indications